EA202090220A2 - СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ВЫСОКОМОЛЕКУЛЯРНОГО vWF В КУЛЬТУРЕ КЛЕТОК - Google Patents
СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ВЫСОКОМОЛЕКУЛЯРНОГО vWF В КУЛЬТУРЕ КЛЕТОКInfo
- Publication number
- EA202090220A2 EA202090220A2 EA202090220A EA202090220A EA202090220A2 EA 202090220 A2 EA202090220 A2 EA 202090220A2 EA 202090220 A EA202090220 A EA 202090220A EA 202090220 A EA202090220 A EA 202090220A EA 202090220 A2 EA202090220 A2 EA 202090220A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cell culture
- specific activity
- producing recombinant
- present
- high specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится, среди прочих аспектов, к условиям культивирования клеток для получения высокомолекулярного vWF, в частности WF, состоящего из большого количества мультимеров, с высокой удельной активностью и ADAMTS13 с высокой удельной активностью. Условия культивирования клеток согласно настоящему изобретению могут включать, например, среду для клеточной культуры с повышенной концентрацией меди и/или супернатант культуры клеток с низкой концентрацией аммония (NH). Настоящее изобретение также обеспечивает способы культивирования клеток в условиях клеточной культуры для экспрессии высокомолекулярных vWF и rA13, обладающих высокой удельной активностью.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36263510P | 2010-07-08 | 2010-07-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA202090220A2 true EA202090220A2 (ru) | 2020-05-31 |
EA202090220A3 EA202090220A3 (ru) | 2020-08-31 |
Family
ID=44514323
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090067A EA202090067A3 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного adamts13 в культуре клеток |
EA202090220A EA202090220A3 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного высокомолекулярного vwf в культуре клеток |
EA201792340A EA035147B1 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного adamts13 в культуре клеток |
EA201390082A EA029503B1 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного adamts13 в культуре клеток |
EA201390080A EA035066B1 (ru) | 2010-07-08 | 2011-07-08 | СПОСОБ ПОЛУЧЕНИЯ КУЛЬТУРАЛЬНОЙ ЖИДКОСТИ КЛЕТОК МЛЕКОПИТАЮЩЕГО, СОДЕРЖАЩЕЙ ВЫСОКОМОЛЕКУЛЯРНЫЙ РЕКОМБИНАНТНЫЙ ФАКТОР ФОН ВИЛЛЕБРАНДА (rVWF) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090067A EA202090067A3 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного adamts13 в культуре клеток |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792340A EA035147B1 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного adamts13 в культуре клеток |
EA201390082A EA029503B1 (ru) | 2010-07-08 | 2011-07-08 | Способ получения рекомбинантного adamts13 в культуре клеток |
EA201390080A EA035066B1 (ru) | 2010-07-08 | 2011-07-08 | СПОСОБ ПОЛУЧЕНИЯ КУЛЬТУРАЛЬНОЙ ЖИДКОСТИ КЛЕТОК МЛЕКОПИТАЮЩЕГО, СОДЕРЖАЩЕЙ ВЫСОКОМОЛЕКУЛЯРНЫЙ РЕКОМБИНАНТНЫЙ ФАКТОР ФОН ВИЛЛЕБРАНДА (rVWF) |
Country Status (25)
Country | Link |
---|---|
US (8) | US8852888B2 (ru) |
EP (6) | EP3392271B8 (ru) |
JP (3) | JP6138683B2 (ru) |
KR (4) | KR102007773B1 (ru) |
CN (4) | CN107286235A (ru) |
AU (6) | AU2011274470B2 (ru) |
BR (2) | BR112013000515B1 (ru) |
CA (2) | CA2804275A1 (ru) |
CO (2) | CO6690745A2 (ru) |
DK (3) | DK2590998T3 (ru) |
EA (5) | EA202090067A3 (ru) |
ES (4) | ES2761692T5 (ru) |
FI (1) | FI3064508T4 (ru) |
HR (3) | HRP20192089T4 (ru) |
HU (3) | HUE046443T2 (ru) |
IL (5) | IL286298B (ru) |
MX (3) | MX353409B (ru) |
NZ (2) | NZ605403A (ru) |
PL (4) | PL2591094T3 (ru) |
PT (3) | PT2591094T (ru) |
SG (3) | SG186935A1 (ru) |
SI (3) | SI3064508T2 (ru) |
TR (1) | TR201815211T4 (ru) |
TW (4) | TWI617575B (ru) |
WO (2) | WO2012006591A1 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009322367B2 (en) * | 2008-12-05 | 2015-03-26 | Takeda Pharmaceutical Company Limited | Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
TR201815211T4 (tr) | 2010-07-08 | 2018-11-21 | Baxalta GmbH | Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem. |
KR102319868B1 (ko) * | 2011-06-10 | 2021-11-01 | 다케다 야쿠힌 고교 가부시키가이샤 | 재조합 vwf의 투여에 의한 응고 질환의 치료 |
US9030963B2 (en) * | 2012-12-03 | 2015-05-12 | Honeywell International Inc. | Analyzing a network topology |
UY35343A (es) * | 2013-02-26 | 2014-09-30 | Bayer Healthcare Llc | Formulaciones y procedimientos para la producción de proteína recombinante aumentada |
US20140271622A1 (en) * | 2013-03-14 | 2014-09-18 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
WO2015158851A1 (en) * | 2014-04-16 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
WO2015188224A1 (en) * | 2014-06-13 | 2015-12-17 | Csl Limited | Improved production of recombinant von willebrand factor in a bioreactor |
MA41685A (fr) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère |
CA2973343C (en) * | 2015-02-05 | 2023-08-08 | R.P. Scherer Technologies, Llc | Activated formylglycine-generating enzymes and methods of producing and using the same |
AR104050A1 (es) * | 2015-03-26 | 2017-06-21 | Chugai Pharmaceutical Co Ltd | Proceso de producción con iones de cobre controlados |
TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
BR112019002194A2 (pt) | 2016-08-04 | 2019-05-21 | Baxalta GmbH | uso de adamts13 para tratar, melhorar e/ou prevenir a crise vaso-oclusiva na doença falciforme, lesão pulmonar aguda e/ou síndrome da insuficiência respiratória aguda |
CN106957815B (zh) * | 2017-03-16 | 2021-05-07 | 杨涛 | 一种用于人类多潜能干细胞的无血清培养基的配方 |
RU2766118C2 (ru) | 2017-07-07 | 2022-02-08 | Такеда Фармасьютикал Компани Лимитед | Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв |
WO2019010497A1 (en) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION |
WO2019183290A1 (en) | 2018-03-21 | 2019-09-26 | Baxalta Incorporated | Separation of vwf and vwf propeptide by chromatographic methods |
JP2022524291A (ja) | 2019-02-01 | 2022-05-02 | 武田薬品工業株式会社 | 組換えVWF(rVWF)を使用する予防治療法 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10961500B1 (en) | 2019-04-23 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Cell culture medium for eukaryotic cells |
US20220401524A1 (en) | 2019-09-11 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Methods of treatment related to complexes of von willebrand factor and complement c1q |
EP4100048A1 (en) | 2020-02-04 | 2022-12-14 | Takeda Pharmaceutical Company Limited | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf |
WO2021234458A1 (en) | 2020-05-22 | 2021-11-25 | Takeda Pharmaceutical Company Limited | Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
NL8500961A (nl) | 1985-04-01 | 1986-11-03 | Stichting Vrienden Van De Stic | Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten. |
JPS62502589A (ja) | 1985-04-11 | 1987-10-08 | ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン | フオン・ビルブラント因子 |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
WO1996015231A2 (en) | 1994-11-10 | 1996-05-23 | Immuno Aktiengesellschaft | Method for producing biologicals in protein-free culture |
JP3649249B2 (ja) | 1995-02-23 | 2005-05-18 | クエスト・インターナショナル・サービシーズ・ビー・ブイ | 組織および細胞培養用ペプチド |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
AU4330597A (en) | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6103529A (en) | 1996-10-10 | 2000-08-15 | Life Technologies, Inc. | Animal cell culture media comprising peptides derived from rice |
WO1998041611A1 (en) | 1997-03-20 | 1998-09-24 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
JP2001120262A (ja) * | 1999-10-26 | 2001-05-08 | Welfide Corp | 生理活性物質の産生増強方法 |
US6926894B2 (en) * | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
KR20040065231A (ko) * | 2001-11-28 | 2004-07-21 | 산도즈 게엠베하 | 세포 배양 방법 |
WO2003054172A2 (en) * | 2002-01-17 | 2003-07-03 | Lonza Biologics Plc. | Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
US20050084828A1 (en) | 2003-10-21 | 2005-04-21 | The University Of North Carolina At Chapel Hill | Apparatus and method for braille instruction |
EP1593388A1 (en) | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
TWI384069B (zh) * | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
US8273553B2 (en) | 2004-11-02 | 2012-09-25 | Ares Trading S.A. | Production of growth hormone in serum-free cell culture medium for mammalian cells |
JP4833991B2 (ja) * | 2004-11-02 | 2011-12-07 | アレス トレーディング ソシエテ アノニム | 哺乳動物細胞のための無血清細胞培養培地 |
US20070049557A1 (en) | 2005-08-24 | 2007-03-01 | Hashim Ahmed | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers |
EP2522717B1 (en) | 2006-01-04 | 2014-04-02 | Baxter International Inc | Oligopeptide-free cell culture media |
US20070190057A1 (en) * | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
CN101490239A (zh) * | 2006-07-14 | 2009-07-22 | 帝斯曼知识产权资产管理有限公司 | 改进的细胞培养方法 |
TW201516149A (zh) * | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
US7960869B2 (en) | 2006-09-22 | 2011-06-14 | Siemens Industry, Inc. | Internal intelligence for remote operated relay |
EP2114458B1 (en) * | 2006-12-27 | 2014-02-26 | Nektar Therapeutics | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
AU2008223133A1 (en) * | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
DE102007046611A1 (de) * | 2007-09-28 | 2009-04-02 | Osram Opto Semiconductors Gmbh | Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung |
DK2235197T3 (en) * | 2007-12-27 | 2017-10-09 | Baxalta GmbH | Methods of cell culture |
HUE043863T2 (hu) | 2007-12-31 | 2019-09-30 | Baxalta GmbH | Lényegében állati fehérjétõl mentes rekombináns furin és eljárás elõállítására |
JP4458167B2 (ja) * | 2008-01-11 | 2010-04-28 | 住友金属工業株式会社 | 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法 |
WO2009116044A2 (en) | 2008-03-19 | 2009-09-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compounds for treating bacterial infections |
WO2009129379A1 (en) * | 2008-04-17 | 2009-10-22 | Wyeth | Methods for enhanced production of bone morphogenetic proteins |
US8486699B2 (en) * | 2008-05-23 | 2013-07-16 | The United States Of America As Represented By The Secretary Of Agriculture | Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
BR122021005965B1 (pt) * | 2009-07-31 | 2022-01-25 | Baxalta Incorporated | Método para produzir uma composição de desintegrina e metaloproteinase com motivo trombospondina (adamts) |
TR201815211T4 (tr) | 2010-07-08 | 2018-11-21 | Baxalta GmbH | Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem. |
TWI408228B (zh) | 2010-10-29 | 2013-09-11 | Univ Nat Chunghsing | 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法 |
-
2011
- 2011-07-08 TR TR2018/15211T patent/TR201815211T4/tr unknown
- 2011-07-08 SG SG2013000799A patent/SG186935A1/en unknown
- 2011-07-08 US US13/179,386 patent/US8852888B2/en active Active
- 2011-07-08 CA CA2804275A patent/CA2804275A1/en not_active Abandoned
- 2011-07-08 US US13/179,399 patent/US9458222B2/en active Active
- 2011-07-08 PL PL11738351T patent/PL2591094T3/pl unknown
- 2011-07-08 HU HUE16153131A patent/HUE046443T2/hu unknown
- 2011-07-08 PL PL11736502T patent/PL2590998T3/pl unknown
- 2011-07-08 NZ NZ605403A patent/NZ605403A/en unknown
- 2011-07-08 PL PL16153131.4T patent/PL3064508T5/pl unknown
- 2011-07-08 TW TW100124395A patent/TWI617575B/zh active
- 2011-07-08 JP JP2013518871A patent/JP6138683B2/ja active Active
- 2011-07-08 AU AU2011274470A patent/AU2011274470B2/en active Active
- 2011-07-08 PT PT11738351T patent/PT2591094T/pt unknown
- 2011-07-08 EA EA202090067A patent/EA202090067A3/ru unknown
- 2011-07-08 DK DK11736502.3T patent/DK2590998T3/en active
- 2011-07-08 EP EP18175765.9A patent/EP3392271B8/en active Active
- 2011-07-08 KR KR1020187024672A patent/KR102007773B1/ko active IP Right Grant
- 2011-07-08 TW TW100124394A patent/TWI609890B/zh active
- 2011-07-08 EA EA202090220A patent/EA202090220A3/ru unknown
- 2011-07-08 EA EA201792340A patent/EA035147B1/ru not_active IP Right Cessation
- 2011-07-08 KR KR1020187034201A patent/KR102027991B1/ko active IP Right Grant
- 2011-07-08 SI SI201131818T patent/SI3064508T2/sl unknown
- 2011-07-08 SG SG2013000815A patent/SG186936A1/en unknown
- 2011-07-08 PL PL18175765T patent/PL3392271T3/pl unknown
- 2011-07-08 EP EP11736502.3A patent/EP2590998B1/en active Active
- 2011-07-08 FI FIEP16153131.4T patent/FI3064508T4/fi active
- 2011-07-08 EA EA201390082A patent/EA029503B1/ru not_active IP Right Cessation
- 2011-07-08 WO PCT/US2011/043455 patent/WO2012006591A1/en active Application Filing
- 2011-07-08 EA EA201390080A patent/EA035066B1/ru not_active IP Right Cessation
- 2011-07-08 MX MX2015014216A patent/MX353409B/es unknown
- 2011-07-08 CN CN201710611592.4A patent/CN107286235A/zh active Pending
- 2011-07-08 IL IL286298A patent/IL286298B/en unknown
- 2011-07-08 ES ES16153131T patent/ES2761692T5/es active Active
- 2011-07-08 PT PT117365023T patent/PT2590998T/pt unknown
- 2011-07-08 CA CA2805557A patent/CA2805557A1/en not_active Abandoned
- 2011-07-08 EP EP16153131.4A patent/EP3064508B2/en active Active
- 2011-07-08 PT PT161531314T patent/PT3064508T/pt unknown
- 2011-07-08 EP EP21170129.7A patent/EP3909977A1/en active Pending
- 2011-07-08 WO PCT/US2011/043459 patent/WO2012006594A1/en active Application Filing
- 2011-07-08 BR BR112013000515-7A patent/BR112013000515B1/pt active IP Right Grant
- 2011-07-08 JP JP2013518869A patent/JP5953502B2/ja active Active
- 2011-07-08 SI SI201131603T patent/SI2591094T1/sl unknown
- 2011-07-08 CN CN201711432166.0A patent/CN108060154A/zh active Pending
- 2011-07-08 AU AU2011274467A patent/AU2011274467B2/en active Active
- 2011-07-08 HU HUE11736502A patent/HUE038193T2/hu unknown
- 2011-07-08 DK DK16153131.4T patent/DK3064508T4/da active
- 2011-07-08 EP EP19191438.1A patent/EP3626736A1/en active Pending
- 2011-07-08 KR KR1020137003278A patent/KR101924120B1/ko active IP Right Grant
- 2011-07-08 DK DK11738351.3T patent/DK2591094T3/en active
- 2011-07-08 MX MX2013000166A patent/MX2013000166A/es active IP Right Grant
- 2011-07-08 TW TW105121378A patent/TWI646972B/zh active
- 2011-07-08 CN CN2011800431007A patent/CN103097409A/zh active Pending
- 2011-07-08 BR BR112013000512A patent/BR112013000512A2/pt not_active Application Discontinuation
- 2011-07-08 MX MX2013000165A patent/MX339632B/es active IP Right Grant
- 2011-07-08 HR HRP20192089TT patent/HRP20192089T4/hr unknown
- 2011-07-08 HU HUE11738351A patent/HUE11738351T2/hu unknown
- 2011-07-08 ES ES18175765T patent/ES2875772T3/es active Active
- 2011-07-08 SG SG10201809632XA patent/SG10201809632XA/en unknown
- 2011-07-08 ES ES11736502.3T patent/ES2664392T3/es active Active
- 2011-07-08 KR KR1020137003277A patent/KR101894604B1/ko active IP Right Grant
- 2011-07-08 NZ NZ605404A patent/NZ605404A/en unknown
- 2011-07-08 ES ES11738351.3T patent/ES2694518T3/es active Active
- 2011-07-08 CN CN2011800430945A patent/CN103097522A/zh active Pending
- 2011-07-08 EP EP11738351.3A patent/EP2591094B1/en active Active
- 2011-07-08 SI SI201131409T patent/SI2590998T1/en unknown
- 2011-07-08 TW TW107130377A patent/TWI670073B/zh active
-
2012
- 2012-12-27 IL IL223930A patent/IL223930A/en active IP Right Grant
- 2012-12-27 IL IL223929A patent/IL223929A/en active IP Right Grant
-
2013
- 2013-02-07 CO CO13025488A patent/CO6690745A2/es unknown
- 2013-02-07 CO CO13025476A patent/CO6680636A2/es unknown
-
2014
- 2014-07-23 US US14/339,319 patent/US9409971B2/en active Active
- 2014-09-03 US US14/476,580 patent/US20150056657A1/en not_active Abandoned
-
2015
- 2015-07-27 AU AU2015207811A patent/AU2015207811B2/en active Active
-
2016
- 2016-07-01 US US15/201,125 patent/US9834591B2/en active Active
-
2017
- 2017-05-09 US US15/591,022 patent/US10100099B2/en active Active
- 2017-08-01 JP JP2017149409A patent/JP2017217004A/ja active Pending
- 2017-10-30 IL IL255327A patent/IL255327B/en active IP Right Grant
-
2018
- 2018-01-10 AU AU2018200206A patent/AU2018200206B2/en active Active
- 2018-01-24 HR HRP20180136TT patent/HRP20180136T1/hr unknown
- 2018-09-07 US US16/125,141 patent/US10822394B2/en active Active
- 2018-10-12 HR HRP20181657TT patent/HRP20181657T1/hr unknown
-
2020
- 2020-03-15 IL IL273304A patent/IL273304B/en unknown
- 2020-05-29 AU AU2020203565A patent/AU2020203565B2/en active Active
- 2020-10-30 US US17/086,072 patent/US11780904B2/en active Active
-
2022
- 2022-01-05 AU AU2022200035A patent/AU2022200035A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090220A2 (ru) | СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ВЫСОКОМОЛЕКУЛЯРНОГО vWF В КУЛЬТУРЕ КЛЕТОК | |
EA201171018A1 (ru) | Биореактор для культивирования клеток млекопитающих | |
BR112013002811A2 (pt) | meios básicos simplificados para cultura celular pluripotente de humano | |
EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
EA201270224A1 (ru) | Среда для культивирования клеток для экспрессии белков adamts | |
TR201908404T4 (tr) | İşlenmiş yüksek afinite insan t hücresi reseptörleri. | |
RU2009129235A (ru) | Способ получения трансгенных мышей | |
MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
MX2015017110A (es) | Integracion dirigida. | |
DE112010005605A5 (de) | VERFAHREN ZUM KONTAKTIEREN UND Verfahren zum Kontaktieren und Verschalten von Solarzellen und damit hergestellter Solarzellenverbund | |
WO2011159684A3 (en) | Generation of induced pluripotent stem cells from small volumes of peripheral blood | |
DE602005021379D1 (de) | System und verfahren zur produktion von antikörpern in der pflanzenzellkultur | |
EA201491526A1 (ru) | Способ культивирования бычьих и свиных сперматогониальных стволовых клеток без использования клеток-фидеров | |
BR112013027860A2 (pt) | ácido nucleico isolado, planta ou célula vegetal, método para aumentar a capacidade do dreno, acelerar a remobilização e/ou a senescência e a secagem de grão em uma planta, método para aumentar a tolerância a seca na ausência de uma penalidade de produtividade sob condições sem seca, cassete de expressão e método para reduzir a expressão de zmme293 ou a atividade de zmme293 em uma planta | |
WO2013016724A3 (en) | Decarboxylase proteins with high keto-isovalerate decarboxylase activity | |
RU2015120576A (ru) | Бета-глюкозидаза из magnaporthe grisea | |
MY171544A (en) | A cell with reduced ppgppase activity | |
EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
EA201390215A1 (ru) | Композиции и способы получения дендритных клеток | |
WO2012142094A3 (en) | Compositions and methods for increased ethanol production from biomass | |
AR087980A1 (es) | Actividad de dnasa endogena para reducir el contenido de adn | |
EA201400877A1 (ru) | Микроорганизмы, ферментирующие пентозы | |
BRPI0914805B8 (pt) | método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição | |
SG146623A1 (en) | Rodent expression systems utilising polyoma virus and epstein barr virus sequences | |
MX2017014663A (es) | Metodo para producir una proteina recombinante. |